Class A · CUSIP 92337R101 · who reports it, how much, and how much it matters to them
38 of the 720 hedge fund managers we track reported shares of Vera Therapeutics, Inc. (Nasdaq: VERA) on Form 13F for 30 June 2026. Between them they reported USD 1bn. The largest position belongs to Avoro Capital Advisors, at USD 246m. The manager with the most riding on it is Kynam Capital Management, where it is 6.9% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Avoro Capital Advisors1 fund on PPLI.com | USD 246m | 2.2% |
| 2 | Deep Track Capital1 fund on PPLI.com | USD 172m | 2.5% |
| 3 | Kynam Capital Management1 fund on PPLI.com | USD 124m | 6.9% |
| 4 | Sofinnova Investments1 fund on PPLI.com | USD 120m | 6.2% |
| 5 | Eversept Partners3 funds on PPLI.com | USD 95m | 4.9% |
| 6 | Logos Global Management1 fund on PPLI.com | USD 94m | 4.1% |
| 7 | Great Point Partners2 funds on PPLI.com | USD 26m | 4.9% |
| 8 | Braidwell12 funds on PPLI.com | USD 24m | 0.9% |
| 9 | Rock Springs Capital Management2 funds on PPLI.com | USD 18m | 0.9% |
| 10 | Balyasny Asset Management25 funds on PPLI.com | USD 16m | 0.0% |
| 11 | Orbimed Advisors1 fund on PPLI.com | USD 16m | 0.3% |
| 12 | Armistice Capital1 fund on PPLI.com | USD 13m | 0.2% |
| 13 | Renaissance Technologies13 funds on PPLI.com | USD 12m | 0.0% |
| 14 | Millennium Management6 funds on PPLI.com | USD 12m | 0.0% |
| 15 | PFM Health Sciences3 funds on PPLI.com | USD 9.6m | 0.8% |
| 16 | Platinum Investment Management11 funds on PPLI.com | USD 4.9m | 1.2% |
| 17 | Engineers Gate Manager1 fund on PPLI.com | USD 4.6m | 0.1% |
| 18 | HighVista Strategies27 funds on PPLI.com | USD 4.5m | 1.0% |
| 19 | Squarepoint Ops7 funds on PPLI.com | USD 4.5m | 0.0% |
| 20 | Two Sigma Investments35 funds on PPLI.com | USD 4.5m | 0.0% |
| 21 | Boothbay Fund Management2 funds on PPLI.com | USD 4.3m | 0.1% |
| 22 | Exome Asset Management2 funds on PPLI.com | USD 4.2m | 2.6% |
| 23 | D. E. Shaw & Co.15 funds on PPLI.com | USD 3.2m | 0.0% |
| 24 | Neo Ivy Capital Management1 fund on PPLI.com | USD 2.1m | 0.5% |
| 25 | POINT72 Asset Management17 funds on PPLI.com | USD 1.7m | 0.0% |
| 26 | LMR Partners2 funds on PPLI.com | USD 1.7m | 0.0% |
| 27 | Verdad Advisers6 funds on PPLI.com | USD 1m | 1.0% |
| 28 | Verition Fund Management3 funds on PPLI.com | USD 972,000 | 0.0% |
| 29 | Persistent Asset Partners10 funds on PPLI.com | USD 707,000 | 0.2% |
| 30 | Cinctive Capital Management5 funds on PPLI.com | USD 532,000 | 0.0% |
| 31 | Exoduspoint Capital Management7 funds on PPLI.com | USD 480,000 | 0.0% |
| 32 | Nine Masts Capital1 fund on PPLI.com | USD 405,000 | 0.0% |
| 33 | Marshall Wace LLP84 funds on PPLI.com | USD 323,000 | 0.0% |
| 34 | Entrypoint Capital1 fund on PPLI.com | USD 311,000 | 0.1% |
| 35 | Magnetar Financial93 funds on PPLI.com | USD 300,000 | 0.0% |
| 36 | Bayforest Capital1 fund on PPLI.com | USD 122,000 | 0.1% |
| 37 | The Quarry1 fund on PPLI.com | USD 62,650 | 0.0% |
| 38 | Graticule Asia Macro Advisors8 funds on PPLI.com | USD 11,157 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Kynam Capital Management | USD 124m | 6.9% |
| 2 | Sofinnova Investments | USD 120m | 6.2% |
| 3 | Eversept Partners | USD 95m | 4.9% |
| 4 | Great Point Partners | USD 26m | 4.9% |
| 5 | Logos Global Management | USD 94m | 4.1% |
| 6 | Exome Asset Management | USD 4.2m | 2.6% |
| 7 | Deep Track Capital | USD 172m | 2.5% |
| 8 | Avoro Capital Advisors | USD 246m | 2.2% |
| 9 | Platinum Investment Management | USD 4.9m | 1.2% |
| 10 | HighVista Strategies | USD 4.5m | 1.0% |
Vera Therapeutics, Inc. trades under the symbol VERA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 92337R101.
38 of the 720 hedge fund managers PPLI.com tracks reported Vera Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Avoro Capital Advisors (USD 246m), Deep Track Capital (USD 172m), Kynam Capital Management (USD 124m), Sofinnova Investments (USD 120m) and Eversept Partners (USD 95m).
38 managers in our coverage reported it, and between them they run 413 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Kynam Capital Management, where the position was 6.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Vera Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.